Intervention timing and disease stage shape tecovirimat and cidofovir efficacy in male SCID mice

Currently, mpox virus (MPXV) continues to pose a global public health challenge, with immunocompromised individuals often exhibiting more severe clinical symptoms. This study screens three male mouse models (ICR, IFNAR1<sup>-/-</sup>, SCID) and identifies SCID mice as the optimal model for modeling severe patient symptoms, including pneumonia, rash, and localized inflammation, which is applied to evaluate the antiviral efficacy of tecovirimat and cidofovir. Both drugs prevent systemic MPXV spread when administered within two days post virus exposure. Local antiviral efficacy differs between the two drugs, particularly after intradermal infection. Prolonged treatment up to 28 days post infection results in 100% survival of SCID mice but fails to effectively suppress localized rash and inflammatory swelling, suggesting that the drugs have limited impact at later stages of the disease. These findings indicate that the therapeutic efficacy of tecovirimat and cidofovir depends on the timing of intervention initiation and the stage of disease progression.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-12-18
DOI
https://doi.org/10.1038/s41467-025-67548-0
Primary Topic
Poxvirus research and outbreaks
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intervention timing and disease stage shape tecovirimat and cidofovir efficacy in male SCID mice

Huijun Lu, Chao Shang, Xiangshu Qiu, Hao Zhou et al.
Nature Communications
Poxvirus research and outbreaks
article

Intervention timing and disease stage shape tecovirimat and cidofovir efficacy in male SCID mice

Huijun Lu, Chao Shang, Xiangshu Qiu, Hao Zhou, Peng Wang, He Zhang, Li Xiao, Ning Shi, Yubiao Xie, Jiaxin Tian, Yuelong Shu, Bocheng Liu, Xinyu Cao
article en

Abstract

Currently, mpox virus (MPXV) continues to pose a global public health challenge, with immunocompromised individuals often exhibiting more severe clinical symptoms. This study screens three male mouse models (ICR, IFNAR1<sup>-/-</sup>, SCID) and identifies SCID mice as the optimal model for modeling severe patient symptoms, including pneumonia, rash, and localized inflammation, which is applied to evaluate the antiviral efficacy of tecovirimat and cidofovir. Both drugs prevent systemic MPXV spread when administered within two days post virus exposure. Local antiviral efficacy differs between the two drugs, particularly after intradermal infection. Prolonged treatment up to 28 days post infection results in 100% survival of SCID mice but fails to effectively suppress localized rash and inflammatory swelling, suggesting that the drugs have limited impact at later stages of the disease. These findings indicate that the therapeutic efficacy of tecovirimat and cidofovir depends on the timing of intervention initiation and the stage of disease progression.

Nature CommunicationsVol. 17(1)
Jilin University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Changchun Institute of Optics, Fine Mechanics and Physics (CN), Changchun Institute of Applied Chemistry (CN), Chinese Academy of Agricultural Sciences (CN), Institute of Special Animal and Plant Sciences (CN), Zhejiang University (CN)
Guangzhou Medical University, National Key Research and Development Program of China
Openalex Percentile: Top 56%
Poxvirus research and outbreaks
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.